Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Healthcare Consortium To Match Patients To Clinical Trials Via Data Sharing

XTALKS VITALS NEWS

Clinical Trials

The consortium is a culmination of various hospitals’ individual efforts to improve precision medicine treatment options for cancer patients.

Share this!

June 7, 2016 | by Sarah Massey, M.Sc.

Medical Centers from around the country – including Stanford Cancer Institute, Intermountain Healthcare, Providence Health & Services and Syapse – have founded a consortium aimed at using data sharing to improve patient access to cancer clinical trials. Using a software platform, the Oncology Precision Network (OPN) will share genomic data collected from cancer patients.

The consortium is a culmination of various hospitals’ individual efforts to improve precision medicine treatment options for cancer patients. The Swedish Cancer Institute, in collaboration with Providence Health & Services, previously developed an algorithm capable of matching patients with specific molecular types of cancer with clinical trials that may offer them the most clinical benefit.

Tweet: #Cancer patients at small hospitals excluded from #clinicaltrials. http://ctt.ec/Ibjdp+ Cancer patients treated at smaller hospitals as opposed to the large, high-volume cancer centers, may be excluded from participation in clinical trials. According to the OPN, their efforts will improve the accessibility of personalized treatments and clinical trials to those patients who have historically been underserved.



“The highest quality cancer care is predicated on clinical trial participation and currently very few cancer patients can access trials that are matched based on the genetic make-up of their cancer,” said Dr. Thomas Brown, executive director of the Swedish Cancer Institute and co-chair Providence Health & Services Personalized Medicine Program. “This partnership will further our efforts to provide customized therapies that are based on the biological features of both the patient and their unique cancer.”

The data included in the consortium has been collected from 79 hospitals and 800 clinics across 11 US states. The initiative will start with around 100,000 sets of data in its database, with plans to increase the number of healthcare sites involved in the program later this year.

The datasets included will contain patient information including health history, cancer status, molecular and genetic data, treatments, diagnostic results and patient outcomes. Using Syapse’s technology, the data will be shared among the members of the health network.

“This dynamic network will also allow us to approach precision oncology from a 'big data' point of view,” said Dr. Jim Ford, associate professor of medicine (oncology) and genetics at Stanford and director of clinical cancer genomics at the Stanford Cancer Institute. “By aggregating all of our real patient experiences, we will rapidly expand our ability to learn how to choose the best targeted treatments for our cancer patients based on the molecular profile of their tumor and our informatics based research.”


Keywords: Clinical Trials, Cancer, Data Sharing


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Gilead’s Newest Hepatitis C Drug Gets FDA Approval

July 21, 2017 - Dominant player in the chronic hepatitis C virus (HCV) market Gilead has received US Food and Drug Administration (FDA) approval for its newest treatment, Vosevi.

Featured In: Pharmaceutical News


Detecting Alzheimer’s Biomarkers in the Blood Could Improve Early Diagnosis

July 20, 2017 - In an effort to improve rates of early diagnosis and intervention, researchers at Washington University in St. Louis have developed a blood test that can detect some of the hallmarks of Alzheimer’s disease.

Featured In: Biotech News


Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.